Fig. 6.

Outcomes of two patients who developed class II donor-specific antibodies (DSA) 3–4 years posttransplant associated with the onset of proteinuria with minimal changes in allograft function. The biopsy for one patient is shown, but both patients had similar findings of transplant glomerulopathy. Both patients showed a significant reduction in class II DSAs, with stabilization of renal function and some reduction in proteinuria after treatment with intravenously administered immunoglobulin (IVIG) + rituximab